INX-315-01 - Mater Research

INX-315-01

This study will investigate the use of a new medicine called INX-315 which may be used in the future as a possible treatment for advanced solid tumours.

Category
Medical Oncology
Trial status
Recruiting
Trial phase
Phase 1 Drug Trial
Early stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
Registry listing
NCT05735080
ERM Project ID
94092

Trial contact details

Contact person
Caitlin Bennett
Email
Caitlin.Bennett@mater.org.au
Phone
07 3163 7689

What you need to know

Who can take part?

Patients with advanced solid tumour and standard therapy has either been exhausted or is not available

What is involved for you?

The study drug is in a tablet form that you take on a daily basis. You will be required to attend the clinic at least every 1-2 weeks in the first three months of treatment for a physical assessment, blood tests, ECGs and ongoing assessments. You will also receive ongoing tumour assessments via scans.

Back to all Current clinical trials